EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Multiomics Analysis Reveals a Migrasome‐Related Signature for Prognosis and Immunotherapy Response in Lung Adenocarcinoma

Jiayu Zhou, Tianye Song, Nengzheng Wang, Ce Liang, Ming Jiang, Xu Zhang iD, Hong Gao iD, Qingqing Feng iD

Human Mutation · 2026

DOI: 10.1155/humu/8778797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, 2026. Verfasst von Jiayu Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China, srrsh.com. Hauptthemen laut MEDLINE: Immunotherapy, Adenocarcinoma of Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Migrasomes, a newly identified subtype of extracellular vesicles generated during cell migration, play crucial roles in tumor microenvironment modulation. However, their systematic characterization in lung adenocarcinoma (LUAD) remains unexplored. This study is aimed at deciphering migrasome‐related molecular features and their clinical significance through multiomics integration.

Methods

We integrated bulk transcriptomes (541 LUAD samples from TCGA/GEO) with single‐cell RNA‐seq (GSE156632). Migrasome‐related genes (MIGgenes) were identified through WGCNA and differential expression analysis. A machine learning framework incorporating 10 algorithms generated 101 combinatorial models, with the optimal prognostic signature (MIGsig) selected via 10‐fold cross‐validation. Biological mechanisms were investigated through ssGSEA, TME analysis, and in vitro validation.

Results

Our analysis revealed significant migrasome activity enrichment in endothelial cells and fibroblasts, with 115 cross‐omics MIGgenes identified including 31 prognostic markers. The Lasso–Cox‐derived 3‐gene signature (GSTM5/DNASE1L3/PDGFB) demonstrated robust predictive performance (training set C index = 0.703; validation set GSE50081 AUC = 0.678). The low‐MIGsig group exhibited characteristic “hot tumor” features, including elevated immune infiltration and higher tumor mutational burden, and significantly improved immunotherapy response rates in the IMvigor210 cohort. Finally, MIGsig‐related genes were further validated by in vitro experiments and public database.

Conclusions

This study establishes the first migrasome‐based prognostic model for LUAD, demonstrating both independent survival prediction capability and clinical utility for identifying immunotherapy beneficiaries. The MIGsig signature provides novel biological insights into migrasome‐mediated tumor–immune interactions and represents a promising tool for precision oncology applications in LUAD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyAdenocarcinoma of LungLung NeoplasmsBiomarkers, TumorHumansMultiomicsPrognosisTumor MicroenvironmentGene Expression Regulation, NeoplasticGene Expression ProfilingTranscriptomeCell MovementComputational BiologyMachine Learning

Stichwörter der Autor:innen

immunotherapy predictionlung adenocarcinomamachine learningmigrasomestumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China, srrsh.com.
  • Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China, hebmu.edu.cn.
  • School of Life Sciences, Fudan University, Shanghai, China, fudan.edu.cn.
  • Center for Genetic Medicine and Department of Otolaryngology-Head and Neck Surgery, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China, zju.edu.cn.
  • Department of Oncology, The Second Hospital of Hebei Medical University, Shijiazhuang, China, hebmu.edu.cn.
  • Department of Pulmonary and Critical Care Medicine, Shanxi Provincial People's Hospital, Taiyuan, China, spph-sx.com.

ORCID-Profile: Xu Zhang, Hong Gao, Qingqing Feng

Zitieren

APA

Zhou, J., Song, T., Wang, N., Liang, C., Jiang, M., Zhang, X., Gao, H., & Feng, Q. (2026). Integrated Multiomics Analysis Reveals a Migrasome‐Related Signature for Prognosis and Immunotherapy Response in Lung Adenocarcinoma. Human Mutation. https://doi.org/10.1155/humu/8778797

Vancouver

Zhou J, Song T, Wang N, Liang C, Jiang M, Zhang X, et al. Integrated Multiomics Analysis Reveals a Migrasome‐Related Signature for Prognosis and Immunotherapy Response in Lung Adenocarcinoma. Human Mutation. 2026. doi:10.1155/humu/8778797

BibTeX
@article{Zhou2026,
  author = {Zhou, Jiayu and Song, Tianye and Wang, Nengzheng and Liang, Ce and Jiang, Ming and Zhang, Xu and Gao, Hong and Feng, Qingqing},
  title = {Integrated Multiomics Analysis Reveals a Migrasome‐Related Signature for Prognosis and Immunotherapy Response in Lung Adenocarcinoma},
  journal = {Human Mutation},
  year = {2026},
  doi = {10.1155/humu/8778797}
}
Kostenlos starten →